1. Neoadjuvant Therapy in HER2-Positive Breast Cancer

4. HER2-Positive Breast Cancer: Introduction

5. HER2-Targeted Therapy

6. Case Study Discussion

7. Why Administer Preoperative Therapy?

8. NAT for Breast Cancer

9. Breast Preservation Rates by Tumor Size: NCDB Results

10. Subtype and Rates of BCS

11. NAT for ILC

12. Impact of NAT on Breast Conservation Rates (HER2+ and TNBC)

14. Individual Patient Relationship of pCR With Disease Outcomes

15. Use of Neoadjuvant Paradigm in Clinical Research

16. NeoSphere Trial Neoadjuvant Pertuzumab and Trastuzumab

17. Lapatinib in Clinical Trial Studies

18. NeoSphere Results

19. KRISTINE/TRIO-021 T-DM1 + Pertuzumab vs TCH + Pertuzumab in HER2+ EBC

20. KRISTINE/TRIO-021 Results

21. KRISTINE/TRIO-021 Results (cont)

22. Sentinel Lymph Node Biopsy After NAC in Node-Positive Patients

23. Case Study Discussion Treatment

24. Barriers and Challenges to Management of Patients With Early-Stage HER2 Breast Cancer

25. Multidisciplinary Team Management for Breast Cancer

26. Key Takeaways Optimal Management of Patients With Early-Stage HER2 Breast Cancer

27. Abbreviations

28. Abbreviations (cont)